During the last session, Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s traded shares were 2.77 million. At the end of the trading day, the stock’s price was $40.45, reflecting an intraday loss of -3.00% or -$1.25. The 52-week high for the AVIR share is $94.17, that puts it down -132.81 from that peak though still a striking 53.72% gain since the share price plummeted to a 52-week low of $18.72. The company’s market capitalization is $3.43B, and the average trade volume was 1.77 million shares over the past three months.
Atea Pharmaceuticals Inc. (AVIR) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 1.60. AVIR has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.05.
Atea Pharmaceuticals Inc. (NASDAQ:AVIR) trade information
Atea Pharmaceuticals Inc. (AVIR) registered a -3.00% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.00% in intraday trading to $40.45 this Thursday, 10/14/21, hitting a weekly high. The stock’s 5-day price performance is -1.41%, and it has moved by 55.70% in 30 days.
The consensus price target of analysts on Wall Street is $57.00, which implies an increase of 29.04% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $55.00 and $60.00 respectively. As a result, AVIR is trading at a discount of -48.33% off the target high and -35.97% off the low.
Atea Pharmaceuticals Inc. (AVIR) estimates and forecasts
Statistics show that Atea Pharmaceuticals Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Atea Pharmaceuticals Inc. (AVIR) shares have gone down -9.99% during the last six months, with a year-to-date growth rate more than the industry average at 247.06% against 7.00. In the rating firms’ projections, revenue will increase 491.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $53.46 million as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $103.46 million by the end of Dec 2021.
While earnings are projected to return 23.60% in 2021.
Atea Pharmaceuticals Inc. is due to release its next quarterly earnings on August 12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s Major holders
Atea Pharmaceuticals Inc. insiders own 18.49% of total outstanding shares while institutional holders control 69.05%, with the float percentage being 84.71%. FMR, LLC is the largest shareholder of the company, while 153 institutions own stock in it. As of Jun 29, 2021, the company held over 12.41 million shares (or 14.99% of all shares), a total value of $266.58 million in shares.
The next largest institutional holding, with 6.41 million shares, is of Cormorant Asset Management, LP’s that is approximately 7.75% of outstanding shares. At the market price on Jun 29, 2021, these shares were valued at $137.72 million.
Also, the Mutual Funds coming in first place with the largest holdings of Atea Pharmaceuticals Inc. (AVIR) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. Data provided on Aug 30, 2021 indicates that Fidelity Growth Company Fund owns about 4.4 million shares. This amounts to just over 5.32 percent of the company’s overall shares, with a $130.91 million market value. The same data shows that the other fund manager holds slightly less at 1.63 million, or about 1.97% of the stock, which is worth about $35.09 million.